Published in AIDS Weekly, December 21st, 1998
In a phase II study of six to 12 months of adefovir dipivoxil treatment in HIV infected patients, HIV from eight of 29 patients developed mutations in reverse transcriptase (RT) potentially attributable to adefovir dipivoxil therapy ("HIV Type 1 Expressing the Lamivudine-Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability in vitro," Journal of Infectious Diseases, January 1999;179(1):92-100).
Recombinant HIV from pre- and posttreatment plasma samples...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.